{"chunk_id": "medquad__chunk_34263", "source": "medquad", "text": "st infection are being used in PML patients with special permission of the U.S. Food and Drug Administration. Hexadecyloxypropyl-Cidofovir (CMX001) is currently being studied as a treatment option for JVC because of its ability to suppress JVC by inhibiting viral DNA replication.\",NINDS,Progressive Multifocal Leukoencephalopathy\nWhat is the outlook for Progressive Multifocal Leukoencephalopathy ?,\"In general, PML has a mortality rate of 30-50 percent in the first few months following diagnosis b"}